February fiscal flows added a $360B+ private sector surplus, boosting liquidity and risk assets; Fed near peak rates.
Systematix continues to prefer Berger Paints India, highlighting its consistent growth outperformance and momentum across both decorative and industrial segments ...
We reached an important milestone in Q4 ahead of our prior expectations. During the quarter, a second customer adopted our AI-driven solution for manufacturing process development known as FTCO. This ...
It had dropped as much as 8.4% during early trading, which marked its biggest intraday decline in a year. The software giant ...
Management anticipates a critical technical milestone within weeks as major scanner vendors release firmware enabling Digimarc software across retail locations. Large-scale rollouts are planned for ...
The figures provide an encouraging snapshot of the world’s second-biggest economy, after it ended 2025 with the slowest growth since the pandemic reopening.
Closed 21 total stores during fiscal 2025 as part of a significant portfolio optimization effort to eliminate underperforming locations. Identified four known store closures scheduled for late in the ...
Micron (MU) will release its second-quarter fiscal 2026 earnings on Wednesday, March 18. The announcement follows a big rally in MU stock. Over the past three months, MU has surged 92%. Moreover, the ...
Cash flow from operations up +10% to €735m in 2025 underpinned by better financial result and operating performance "2025 ...
EBITDA and capacity targets achieved. With SPRING: activities refocused, leaner organization and reduction in the number of countries. 2025 full year resul ...
Bizcommunity.com on MSN
Sectional title gains momentum as South Africa's house prices climb
South Africa’s housing market continued its upward momentum in October 2025, with the latest House Price Indices from Statistics South Africa showing further acceleration in year-on-year growth.
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapiesIncreased focus on PD-L11/VEGF-A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results